We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Intrauterine Ultrasound Contrast Agent Tests Tubal Patency

By MedImaging International staff writers
Posted on 03 Mar 2021
Print article
Image: HyFoSy image of the uterus and fallopian tubes (Photo courtesy of ExEm Foam)
Image: HyFoSy image of the uterus and fallopian tubes (Photo courtesy of ExEm Foam)
A novel medical foam for ultrasound imaging helps assess blockages in the fallopian tubes in women with known or suspected infertility.

Intended for an ultrasound technique called hysterosalpingo foam sonography (HyFoSy), ExEm Foam, a product of ExEm Foam (Nashville, TN, USA), is an air polymer-type A intrauterine foam that offers a highly accurate, less invasive alternative to tubal patency assessment procedures such as laparoscopy or X-ray hysterosalpingography (HSG). The viscous foam is made by mixing the contents of the two ExEM syringes together. A catheter is then used to infuse this foam through the uterine cavity into the fallopian tubes during the HyFoSy procedure.

If the tubes are patent the foam will appear as a thin, bright white line within the fallopian tubes and spill over the ovaries and into the peritoneal cavity; if the white line does not appear, the fallopian tubes might be occluded or blocked. ExEm Foam should not be used during pregnancy, in women with known or suspected lower genital tract inflammation, infection, or vaginal bleeding, following a gynecologic procedure within the last 30 days, or in known or suspected reproductive tract neoplasia. Side effects include pelvic and abdominal pain, vasovagal reactions and associated symptoms such as nausea and faintness, and post-procedure spotting.

“With a growing demand for assisted reproductive technologies and a downward trend for using radiation in women trying to conceive, there is a huge need for a gentler and more patient-friendly tubal patency test,” said Johan Remmerswaal, President of ExEm Foam. “We are proud to be able to fulfill this need with the Foam procedure by quickly, safely and accurately assessing the patency of the fallopian tubes in the comfort of a patient's gynecologist office.”

“For couples experiencing infertility, we must evaluate a number of different aspects of the reproductive system to determine the root cause. Unfortunately, this evaluation can involve a lengthy process and several uncomfortable procedures,” said Professor Mark Hans Emanuel, MD, PhD, of University Medical Center Utrecht (The Netherlands), and co-inventor of ExEM Foam. “Cutting-edge, safe and effective diagnostic procedures, like the Foam procedure, allow us to quickly and as comfortably as possible identify fertility issues and plan the next step in a patient's fertility journey.”

Blockage of the fallopian tubes accounts for infertility in approximately 20% of couples who are having difficulty conceiving.

Related Links:

Print article


Imaging IT

view channel

Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology

The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more

Industry News

view channel

Global Digital X-Ray Market to Surpass USD 14 Billion by 2026

The global market for digital X-ray is projected to grow at a CAGR of more than 7% from around USD 9 billion in 2020 to over USD 14 billion by 2026, amidst all the opportunities and challenges in a significantly... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.